This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the “Company”) relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data.

Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including statements relating to the Company’s business strategy and financial metrics as well as revenue, operating expense and earnings guidance and projections for future periods, relate to future events or the future financial performance of the Company and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology, as well as the negative of such statements. All statements other than statements of historical fact may be deemed to be forward-looking statements, including those concerning any expectations regarding investment returns; any projections of financial information; any statements about historical results that may suggest trends for our business; any statements of the plans, strategies, and objectives of management for future operations; any statements of expectation or belief regarding future events, potential markets or market size, additional indications or technology developments; developments in clinical trials or regulatory review of NeuroStar® Advanced Therapy System for additional indications; and any statements of assumptions underlying any of the items mentioned. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof. Except as required by law, the Company assumes no obligation and does not intend to update these forward-looking statements or to conform these statements to actual results or to changes in the Company’s expectations, assumptions, estimates and projections.
Keith Sullivan
President &
Chief Executive Officer

Steve Furlong
Senior Vice President,
Chief Financial Officer & Treasurer

35+ years of experience

34+ years of experience
Our Mission: Renewing Lives by Transforming Neurohealth

NeuroStar Advanced Therapy for Mental Health

Indication
Adults with Major Depressive Disorder (MDD) who have not benefited from antidepressant medication (17.3 million US adults)

Market Leader
Market leader in TMS for depression with over 4 million treatment sessions and over 110,000 patients treated

Sales & Customer Support
Largest direct sales and customer support team in the industry

Reimbursement
Broad US reimbursement among commercial and government payors

Clinical Dataset
Largest clinical dataset in TMS for depression

Outcomes Registry
Largest depression outcomes registry in the world

Indications & Growth
New indication opportunities and geographic expansion for growth
Patients with Major Depressive Disorder are Underserved

The medical industry has relied on pharmaceuticals as the first line treatment for MDD.

3 out of 5 patients treated with medication are underserved.

MDD is a leading cause of disability and a major contributor to suicide worldwide.

300 million people worldwide living with depression.

- 3.0% incidence rate

Economic burden in US of $210 billion annually.

Need in MDD

1. Lack of Efficacy
2. Intolerable Side Effects

Current Solution: Antidepressant Medications

- US Adults suffering from MDD
- Patients with MDD being treated
- Poorly served

17.3 million
11.2 million
6.2 million

*Source: https://www.who.int/news-room/fact-sheets/detail/depression

2. Per STAR*D patients that have failed one or more antidepressant trial of adequate dose and duration
Limitations of Antidepressant Medications

The largest prospective clinical trial of MDD ever conducted, STAR*D, showed that medication resistance causes a patient’s chance for remission to decrease with each subsequent medication attempt. STAR*D also showed discontinuation due to side effects increase with each medication attempt.
NeuroStar Delivers Proven Results

83% Response and 62% Remission for patients

Clinically Proven Durability Established Over 12 Months

Long-term post-acute treatment

Only NeuroStar has…

Safety Record
- 4 million+ treatment sessions delivered globally
- Over 110,000 patients treated
- Low discontinuation rate from adverse events ~5%\(^1\)

Investigator-initiated Trials
- More than 65 studies with over 1,900 patients
- Wide range of conditions, including anxiety, bipolar disorder, pain, PTSD, addiction, schizophrenia, tinnitus, and others
Only NeuroStar has...

Patented Contact Sensing Technology
Consistent and Repeatable Treatment

- The smallest movements can result in a dramatic loss of the prescribed TMS dose
- Even 1 mm movement away from the head can result in 40% loss of the TMS prescribed dose
- Continuous contact sensing solves this problem

1 mm is the equivalent of 3 grains of salt

Contact Sensing

- Constantly monitors patient contact with the NeuroStar coil and alerts the clinician if the coil loses contact with the scalp or is angled incorrectly

Good Contact

Bad Contact

- Only NeuroStar Advanced Therapy provides real-time feedback about the coil’s angle and contact

Patented Contact Sensing Technology
TrakStar makes automated large-scale data collection feasible

- **World's Largest Depression Outcomes Registry**
  - **>11,999** Total Outcomes Registry patients
  - 2 Outcomes Registry Peer-reviewed Publications\(^1,2\)

- **>110,000** Total NeuroStar patients treated worldwide

- **>64,000** US patients completing ≥20 treatments

---

Only NeuroStar has...

Invested in Understanding the Market

67% of patients with MDD are unhappy with their current treatment

Based on market research study of 500 diagnosed depression patients

Two Distinct Groups

**Struggling Independents**

*NO LONGER TRUST THEIR PHYSICIAN*  
– will seek out other doctor for new treatment

**Challenged Optimists**

*WILLING TO ASK THEIR PHYSICIAN ABOUT NEUROSTAR*

Patients Are Looking for New Treatment Solutions

“Just okay is not okay…”

“I’ve lost hope…”

“There’s got to be something more…”

“I’m going to keep fighting…”
27 Drop-out Points in the Patient Journey

Only NeuroStar has developed the 5-STARS to Success Program to address drop-out points.

5-STARS to Success Program

- **S**: Set Your Foundation
- **T**: Train NeuroStar Advocates
- **A**: Art of Treatment with Reimbursement
- **R**: Reach Existing Patients
- **S**: Source New Patients
And other benefits designed to help NeuroStar practices build awareness and improve NeuroStar access for patients
# Largest Direct Sales and Customer Support Team

<table>
<thead>
<tr>
<th>Position</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>NeuroStar Practice Consultants</td>
<td>29</td>
</tr>
<tr>
<td>Business Development Managers</td>
<td>22</td>
</tr>
<tr>
<td>Field Service and Technical Support</td>
<td>17</td>
</tr>
<tr>
<td>Sales Leaders</td>
<td>12</td>
</tr>
<tr>
<td>Clinical Training Consultants</td>
<td>8</td>
</tr>
<tr>
<td>Reimbursement Specialists and Managers</td>
<td>7</td>
</tr>
<tr>
<td>Customer Service Representatives</td>
<td>6</td>
</tr>
<tr>
<td>Inside Sales Representatives</td>
<td>4</td>
</tr>
</tbody>
</table>
Offered by the Largest National Providers in the Country

- NeuroStar
- greenbrook gb
- Elite DNA Therapy Services
- LifeStance HEALTH
- TRANSFORMATIONS
- SuccessTMS
- Southern California TMS CENTER
- REFRESH Mental Health
- ACTIVE RECOVERY TMS
Widely Reimbursed

95% Coverage
Estimated to cover 95% of total private payor covered lives in the US

Top 25 US Private Insurers
95+ major US private insurers provide coverage policies representing 300 million covered lives

100% Medicare Coverage
61 million covered lives

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>90867</th>
<th>90868</th>
<th>90869</th>
</tr>
</thead>
<tbody>
<tr>
<td>MT Assist and Treatment Session</td>
<td>Treatment Session</td>
<td>Subsequent MT Assist and Treatment Session</td>
<td></td>
</tr>
</tbody>
</table>
Economics

Physician Practices

NeuroStar Advanced Therapy for Mental Health has potential to enhance physician practice economics

- Proven return on investment for physicians
- Meaningful incremental income potential for physician practice
- Recoup capital investment by treating ~12 patients
- Generate ~$8,500 average revenue per patient per course of treatment

Conclusion: 1 patient per month can equal $100,000 in practice revenue
# Competitive Positioning

<table>
<thead>
<tr>
<th>Feature</th>
<th>NeuroStar</th>
<th>BrainsWay</th>
<th>Magstim</th>
<th>MagVenture</th>
<th>NeuroStar</th>
<th>CloudTMS</th>
<th>Nexstim</th>
<th>Mag &amp; More</th>
</tr>
</thead>
<tbody>
<tr>
<td>Practice Consultants</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$10M Marketing including DTC Advertising</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concierge Call Center</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDA-cleared for iTBS Theta Burst</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Contact Sensing</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>World’s Largest MDD Outcomes Registry</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Publications from Depression Registration</td>
<td>12</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

Contact Sensing w/Contact Sensing

**Practice Consultants**: ✔ □ □ □ □ □ □ □

**$10M Marketing including DTC Advertising**: ✔ □ □ □ □ □ □ □

**Concierge Call Center**: ✔ □ □ □ □ □ □ □

**FDA-cleared for iTBS Theta Burst**: ✔ ✔ ✔ ✔ □ □ □ □

**Contact Sensing**: ✔ □ □ □ □ □ □ □

**World’s Largest MDD Outcomes Registry**: ✔ □ □ □ □ □ □ □

**Publications from Depression Registration Trials**: 12 1 □ 1 □ □ □ □
Japan Roadmap
• Primary international focus is on Japan
• Third largest healthcare spend globally
• Single payor healthcare system
• Shonin approval
• Exclusive distribution agreement with Teijin Pharma
• Reimbursement

Estimated TAM in Japan for Treatment Sessions
• Adults Suffering from MDD 2.4 million
• Treated by a Psychiatrist 655,000
• Failed to achieve remission 475,000
• ~$600 Million Addressable Market
Patent Portfolio

Large issued patent portfolio of all TMS companies, protecting our technical advantage and ensuring freedom to operate globally

**Patent Portfolio**
- 41 US / 54 OUS
  Issued or allowed patents
- 5 US / 8 OUS
  Pending patent applications

**Contact Sensing**
- Multiple U.S. patents

**MT Assist**
- U.S. patent

**Iron Core Magnet**
- Multiple U.S. patents
The NeuroStar Difference

**PROOF**
Over 12 years as market leader

**ONLY NEUROSTAR HAS...**
- The world’s largest depression Outcomes Registry
- Proven long term durability
- Contact Sensing
- TrakStar® – manage/track/report
- TouchStar – theta burst
- 28 Publications including 12 in depression registration trials

**PEOPLE**
Team dedicated to your practice success

**ONLY NEUROSTAR PROVIDES...**
- More than 100 team members dedicated to growing NeuroStar practices
- Lifetime support with strength in numbers
- On-site service within 24 hours for non-operational NeuroStar Systems

**PROGRAMS**
Driving market awareness to grow your practice

**ONLY NEUROSTAR WILL SPEND $10+ MILLION IN MARKETING IN 2021 AND HAS...**
- 5-STARS to Success Program
- Precision Pulse Program
- Co-op Marketing
- Stellar Distinctions
- Concierge Call Center
Financial Overview

NeuroStar Advanced Therapy for Mental Health
Worldwide Quarterly Revenue

Q2 2021 Revenue of $14.2M was up 46% from Q2 2020

Q1 2021 Guidance $15.5M
## Results of Operations

<table>
<thead>
<tr>
<th>($ in thousands)</th>
<th>Three Months Ended June 30,</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2020</td>
<td>2021</td>
<td></td>
</tr>
<tr>
<td>Revenues</td>
<td>$9,741</td>
<td>$14,203</td>
<td></td>
</tr>
<tr>
<td>YOY Growth</td>
<td>46%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gross Profit</td>
<td>7,418</td>
<td>11,453</td>
<td></td>
</tr>
<tr>
<td>Gross Margin</td>
<td>76%</td>
<td>81%</td>
<td></td>
</tr>
<tr>
<td>Operating Expenses:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sales and Marketing</td>
<td>8,151 (84%)</td>
<td>9,042 (64%)</td>
<td></td>
</tr>
<tr>
<td>General and Administrative</td>
<td>4,010 (41%)</td>
<td>6,681 (47%)</td>
<td></td>
</tr>
<tr>
<td>Research and Development</td>
<td>2,116 (22%)</td>
<td>2,294 (16%)</td>
<td></td>
</tr>
<tr>
<td>Total Operating Expenses</td>
<td>14,277</td>
<td>18,017</td>
<td></td>
</tr>
<tr>
<td>Loss from Operations</td>
<td>($6,859)</td>
<td>($6,564)</td>
<td></td>
</tr>
<tr>
<td>% of Revenues</td>
<td>-70%</td>
<td>-46%</td>
<td></td>
</tr>
</tbody>
</table>
## Financial Position

($ in thousands)  | As of June 30, 2021 |
---|---|
Cash and Cash Equivalents | $115,783 |
Other Assets | $32,315 |
**Total Assets** | **$148,098** |
Long-term Debt, net | $34,944 |
Convertible Preferred Stock Warrant Liability | $0 |
Convertible Preferred Stock | $0 |
Accumulated Deficit | ($292,946) |
**Total Stockholders’ Equity** | **$97,166**
## U.S. NeuroStar Revenue

<table>
<thead>
<tr>
<th>NeuroStar REVENUE</th>
<th>Q1-19</th>
<th>Q2-19</th>
<th>Q3-19</th>
<th>Q4-19</th>
<th>Q1-20</th>
<th>Q2-20</th>
<th>Q3-20</th>
<th>Q4-20</th>
<th>Q1-21</th>
<th>Q2-21</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total U.S. NeuroStar Revenue ($000)</strong></td>
<td>$3,350</td>
<td>$4,628</td>
<td>$4,616</td>
<td>$5,413</td>
<td>$2,594</td>
<td>$2,338</td>
<td>$2,541</td>
<td>$3,620</td>
<td>$1,755</td>
<td>$2,577</td>
</tr>
<tr>
<td>YoY ∆</td>
<td>41%</td>
<td>30%</td>
<td>18%</td>
<td>14%</td>
<td>-23%</td>
<td>-49%</td>
<td>-45%</td>
<td>-33%</td>
<td>-32%</td>
<td>10%</td>
</tr>
<tr>
<td><strong>U.S. NeuroStar Capital Revenue ($000) (1)</strong></td>
<td>$2,939</td>
<td>$4,034</td>
<td>$4,264</td>
<td>$4,959</td>
<td>$2,410</td>
<td>$2,224</td>
<td>$2,438</td>
<td>$3,446</td>
<td>$1,589</td>
<td>$2,441</td>
</tr>
<tr>
<td>YoY ∆</td>
<td>54%</td>
<td>23%</td>
<td>24%</td>
<td>14%</td>
<td>-18%</td>
<td>-45%</td>
<td>-43%</td>
<td>-31%</td>
<td>-34%</td>
<td>10%</td>
</tr>
<tr>
<td><strong>U.S. NeuroStar Operating Lease Revenue ($000) (2)</strong></td>
<td>$182</td>
<td>$187</td>
<td>$184</td>
<td>$177</td>
<td>$155</td>
<td>$114</td>
<td>$88</td>
<td>$79</td>
<td>$108</td>
<td>$55</td>
</tr>
<tr>
<td>YoY ∆</td>
<td>-29%</td>
<td>3%</td>
<td>-31%</td>
<td>-24%</td>
<td>-15%</td>
<td>-39%</td>
<td>-52%</td>
<td>-55%</td>
<td>-30%</td>
<td>-51%</td>
</tr>
<tr>
<td><strong>U.S. NeuroStar Other ($000) (3)</strong></td>
<td>$229</td>
<td>$407</td>
<td>$167</td>
<td>$278</td>
<td>$29</td>
<td>$0</td>
<td>$15</td>
<td>$96</td>
<td>$58</td>
<td>$81</td>
</tr>
<tr>
<td>YoY ∆</td>
<td>11%</td>
<td>239%</td>
<td>-21%</td>
<td>50%</td>
<td>-87%</td>
<td>-100%</td>
<td>-91%</td>
<td>-66%</td>
<td>100%</td>
<td>100%</td>
</tr>
</tbody>
</table>

(1) = Revenue includes NeuroStar System Capital Sales and Sales Type Leases  
(2) = Revenue derived from Operating Lease revenue amortization during the period  
(3) = Revenue derived from Treatment Coils in U.S.
# U.S. NeuroStar Treatment Sessions

## Total U.S. Treatment Session Revenues ($000)

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1-19</th>
<th>Q2-19</th>
<th>Q3-19</th>
<th>Q4-19</th>
<th>Q1-20</th>
<th>Q2-20</th>
<th>Q3-20</th>
<th>Q4-20</th>
<th>Q1-21</th>
<th>Q2-21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$8,778</td>
<td>$10,847</td>
<td>$10,252</td>
<td>$11,243</td>
<td>$8,193</td>
<td>$6,547</td>
<td>$9,083</td>
<td>$11,029</td>
<td>$9,629</td>
<td>$10,801</td>
</tr>
<tr>
<td>YoY Δ</td>
<td>21%</td>
<td>22%</td>
<td>11%</td>
<td>13%</td>
<td>-7%</td>
<td>-40%</td>
<td>-11%</td>
<td>-2%</td>
<td>18%</td>
<td>65%</td>
</tr>
</tbody>
</table>

## Average Revenue per Active Site ($000) (1)

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1-19</th>
<th>Q2-19</th>
<th>Q3-19</th>
<th>Q4-19</th>
<th>Q1-20</th>
<th>Q2-20</th>
<th>Q3-20</th>
<th>Q4-20</th>
<th>Q1-21</th>
<th>Q2-21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$12.4</td>
<td>$14.7</td>
<td>$13.2</td>
<td>$13.5</td>
<td>$9.4</td>
<td>$7.4</td>
<td>$10.2</td>
<td>$12.1</td>
<td>$10.5</td>
<td>$12.0</td>
</tr>
<tr>
<td>YoY Δ</td>
<td>NM</td>
<td>1%</td>
<td>-9%</td>
<td>-8%</td>
<td>-24%</td>
<td>-50%</td>
<td>-22%</td>
<td>-10%</td>
<td>12%</td>
<td>62%</td>
</tr>
</tbody>
</table>

(1) = Total Treatment Session Revenue / Active Sites (Ending of Prior Quarter)
### Supplemental Financial and Operating Information

#### Revenue ($ thousands)

<table>
<thead>
<tr>
<th></th>
<th>2019 Q1</th>
<th>2019 Q2</th>
<th>2019 Q3</th>
<th>2019 Q4</th>
<th>2020 Q1</th>
<th>2020 Q2</th>
<th>2020 Q3</th>
<th>2020 Q4</th>
<th>2021 Q1</th>
<th>2021 Q2</th>
<th>FY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NeuroStar Capital (1)</strong></td>
<td>$2,939</td>
<td>$4,034</td>
<td>$4,264</td>
<td>$4,959</td>
<td>$2,410</td>
<td>$2,224</td>
<td>$2,438</td>
<td>$3,446</td>
<td>$1,589</td>
<td>$2,441</td>
<td>$16,196</td>
</tr>
<tr>
<td>YoY Change</td>
<td>54%</td>
<td>23%</td>
<td>24%</td>
<td>14%</td>
<td>-18%</td>
<td>-43%</td>
<td>-43%</td>
<td>-31%</td>
<td>-34%</td>
<td>10%</td>
<td>25%</td>
</tr>
<tr>
<td><strong>NeuroStar Operating Lease (2)</strong></td>
<td>$182</td>
<td>$187</td>
<td>$184</td>
<td>$177</td>
<td>$155</td>
<td>$114</td>
<td>$88</td>
<td>$79</td>
<td>$108</td>
<td>$55</td>
<td>$730</td>
</tr>
<tr>
<td>YoY Change</td>
<td>-29%</td>
<td>3%</td>
<td>-31%</td>
<td>-24%</td>
<td>-16%</td>
<td>-33%</td>
<td>-52%</td>
<td>-55%</td>
<td>-31%</td>
<td>-51%</td>
<td>-22%</td>
</tr>
<tr>
<td><strong>Other (3)</strong></td>
<td>$229</td>
<td>$407</td>
<td>$167</td>
<td>$278</td>
<td>$29</td>
<td>$0</td>
<td>$15</td>
<td>$96</td>
<td>$58</td>
<td>$81</td>
<td>$1,081</td>
</tr>
<tr>
<td>YoY Change</td>
<td>11%</td>
<td>23%</td>
<td>-21%</td>
<td>50%</td>
<td>-67%</td>
<td>-100%</td>
<td>-91%</td>
<td>-66%</td>
<td>100%</td>
<td>100%</td>
<td>50%</td>
</tr>
<tr>
<td><strong>Total U.S. NeuroStar Advanced Therapy System Revenues</strong></td>
<td><strong>$3,350</strong></td>
<td><strong>$4,628</strong></td>
<td><strong>$4,616</strong></td>
<td><strong>$5,413</strong></td>
<td><strong>$2,594</strong></td>
<td><strong>$2,338</strong></td>
<td><strong>$2,541</strong></td>
<td><strong>$3,620</strong></td>
<td><strong>$1,755</strong></td>
<td><strong>$2,577</strong></td>
<td><strong>$18,007</strong></td>
</tr>
<tr>
<td>YoY Change</td>
<td>41%</td>
<td>30%</td>
<td>16%</td>
<td>14%</td>
<td>-23%</td>
<td>-49%</td>
<td>-45%</td>
<td>-33%</td>
<td>-32%</td>
<td>10%</td>
<td>23%</td>
</tr>
<tr>
<td><strong>Total U.S. Treatment Sessions Revenues</strong></td>
<td><strong>$8,778</strong></td>
<td><strong>$10,847</strong></td>
<td><strong>$10,252</strong></td>
<td><strong>$11,243</strong></td>
<td><strong>$8,193</strong></td>
<td><strong>$6,547</strong></td>
<td><strong>$9,083</strong></td>
<td><strong>$11,029</strong></td>
<td><strong>$9,629</strong></td>
<td><strong>$10,801</strong></td>
<td><strong>$41,120</strong></td>
</tr>
<tr>
<td>YoY Change</td>
<td>21%</td>
<td>22%</td>
<td>11%</td>
<td>13%</td>
<td>-7%</td>
<td>-40%</td>
<td>-11%</td>
<td>-2%</td>
<td>18%</td>
<td>65%</td>
<td>17%</td>
</tr>
<tr>
<td><strong>Total U.S. Other Revenues</strong></td>
<td><strong>$418</strong></td>
<td><strong>$415</strong></td>
<td><strong>$426</strong></td>
<td><strong>$374</strong></td>
<td><strong>$390</strong></td>
<td><strong>$382</strong></td>
<td><strong>$404</strong></td>
<td><strong>$397</strong></td>
<td><strong>$419</strong></td>
<td><strong>$431</strong></td>
<td><strong>$1,633</strong></td>
</tr>
<tr>
<td>YoY Change</td>
<td>16%</td>
<td>1%</td>
<td>9%</td>
<td>-12%</td>
<td>-7%</td>
<td>-8%</td>
<td>-5%</td>
<td>-6%</td>
<td>7%</td>
<td>13%</td>
<td>3%</td>
</tr>
<tr>
<td><strong>Total U.S. Revenues</strong></td>
<td><strong>$12,546</strong></td>
<td><strong>$15,890</strong></td>
<td><strong>$15,294</strong></td>
<td><strong>$17,030</strong></td>
<td><strong>$11,177</strong></td>
<td><strong>$9,267</strong></td>
<td><strong>$10,209</strong></td>
<td><strong>$15,046</strong></td>
<td><strong>$11,802</strong></td>
<td><strong>$13,809</strong></td>
<td><strong>$60,760</strong></td>
</tr>
<tr>
<td>YoY Change</td>
<td>26%</td>
<td>23%</td>
<td>13%</td>
<td>13%</td>
<td>-11%</td>
<td>-42%</td>
<td>-21%</td>
<td>-12%</td>
<td>6%</td>
<td>49%</td>
<td>18%</td>
</tr>
<tr>
<td><strong>Total International Revenues</strong></td>
<td><strong>$182</strong></td>
<td><strong>$682</strong></td>
<td><strong>$706</strong></td>
<td><strong>$326</strong></td>
<td><strong>$299</strong></td>
<td><strong>$474</strong></td>
<td><strong>$419</strong></td>
<td><strong>$533</strong></td>
<td><strong>$486</strong></td>
<td><strong>$394</strong></td>
<td><strong>$1,186</strong></td>
</tr>
<tr>
<td>YoY Change</td>
<td>1%</td>
<td>93%</td>
<td>22%</td>
<td>-40%</td>
<td>64%</td>
<td>-31%</td>
<td>-41%</td>
<td>64%</td>
<td>63%</td>
<td>-17%</td>
<td>46%</td>
</tr>
<tr>
<td><strong>Total Revenues</strong></td>
<td><strong>$12,728</strong></td>
<td><strong>$16,572</strong></td>
<td><strong>$16,000</strong></td>
<td><strong>$17,356</strong></td>
<td><strong>$11,476</strong></td>
<td><strong>$9,741</strong></td>
<td><strong>$12,448</strong></td>
<td><strong>$15,579</strong></td>
<td><strong>$12,288</strong></td>
<td><strong>$14,203</strong></td>
<td><strong>$62,656</strong></td>
</tr>
<tr>
<td>YoY Change</td>
<td>25%</td>
<td>25%</td>
<td>16%</td>
<td>11%</td>
<td>-10%</td>
<td>-41%</td>
<td>-22%</td>
<td>-10%</td>
<td>7%</td>
<td>46%</td>
<td>19%</td>
</tr>
</tbody>
</table>

#### U.S. Operating and Financial Metrics

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>FY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total NeuroStar Systems Sold (4)</strong></td>
<td><strong>43</strong></td>
<td><strong>61</strong></td>
<td><strong>38</strong></td>
<td><strong>23</strong></td>
</tr>
<tr>
<td>YoY Change</td>
<td>79%</td>
<td>42%</td>
<td>45%</td>
<td>28%</td>
</tr>
<tr>
<td><strong>Average Revenue Per Active Site ($) (5)</strong></td>
<td><strong>$12,415</strong></td>
<td><strong>$14,718</strong></td>
<td><strong>$13,177</strong></td>
<td><strong>$13,497</strong></td>
</tr>
<tr>
<td>YoY Change</td>
<td>NA</td>
<td>29%</td>
<td>17%</td>
<td>17%</td>
</tr>
</tbody>
</table>

(1) = Revenue from Capital Sales and Sales Type Leases
(2) = Revenue derived from Operating Lease revenue during the period
(3) = Primarily includes revenue derived from Treatment Coils in US
(4) = Includes all systems sold during the period, both as Capital Sales or Sales Type Leases
(5) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period)